Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GEORGE CARR

Allopathic & Osteopathic Physicians Family Medicine

NPI
1528032661
CMS profile
114290
Location
JEFFERSON CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$3,092.58

189 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GEORGE CARR

NPI 1528032661 · CMS profile ID 114290

Allopathic & Osteopathic Physicians / Family Medicine

JEFFERSON CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528032661?year=2025&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GEORGE CARR, NPI 1528032661, CMS profile ID 114290. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528032661?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). GEORGE CARR, NPI 1528032661, CMS profile ID 114290. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528032661?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
GEORGE CARR, NPI 1528032661, CMS profile ID 114290, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–189 of 189 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1528032661?year=2025&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

189 matching records · $3,092.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 189 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–189 of 189.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $16.1703/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229930637 CMS
ABBVIE INC. $20.4103/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201610459 CMS
ABBVIE INC. $7.8203/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201610461 CMS
Averitas Pharma Inc. $19.3903/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248545901 CMS
Axsome Therapeutics, Inc. $17.2303/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1235617158 CMS
Lilly USA, LLC $22.2003/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186646481 CMS
ABBVIE INC. $6.1703/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201610457 CMS
Amgen Inc. $15.5903/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228500703 CMS
ABBVIE INC. $15.1703/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201610455 CMS
PFIZER INC. $11.5103/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230047881 CMS
PFIZER INC. $16.3103/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229940828 CMS
SCPHARMACEUTICALS INC. $13.9303/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228177922 CMS
Novo Nordisk Inc $15.2603/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188281196 CMS
Bayer Healthcare Pharmaceuticals Inc. $13.6503/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225487289 CMS
PFIZER INC. $11.7603/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230044416 CMS
PFIZER INC. $13.9202/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229947573 CMS
ABBVIE INC. $15.5502/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201610453 CMS
Takeda Pharmaceuticals U.S.A., Inc. $18.6802/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223846136 CMS
Amgen Inc. $13.7502/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227156391 CMS
PFIZER INC. $12.5602/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230043286 CMS
Novo Nordisk Inc $19.6002/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188132319 CMS
ABBVIE INC. $15.0802/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201610451 CMS
Viatris Specialty LLC $16.4202/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238511819 CMS
Medtronic, Inc. $23.0202/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1218923381 CMS
Novo Nordisk Inc $10.2602/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188604587 CMS
Novo Nordisk Inc $16.4702/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188393637 CMS
PFIZER INC. $13.2902/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230051904 CMS
Phathom Pharmaceuticals, Inc. $18.2402/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219347004 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.3702/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225487283 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.3601/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231888998 CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $14.0201/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1241267705 CMS
IRONWOOD PHARMACEUTICALS, INC $22.6701/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227658235 CMS
PFIZER INC. $16.9301/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229925716 CMS
Novo Nordisk Inc $18.6301/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1188864078 CMS
ABBVIE INC. $11.3801/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201610449 CMS
TOLMAR, INC. $21.8601/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237006221 CMS
ABBVIE INC. $7.0601/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201610447 CMS
Otsuka America Pharmaceutical, Inc. $15.8501/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227304781 CMS
PFIZER INC. $12.1101/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1230052026 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,706.61 149
PY2020 $1,322.07 92
PY2021 $1,918.16 123
PY2022 $2,400.35 153
PY2023 $2,573.59 164
PY2024 $4,622.57 191
PY2025 $3,092.58 189

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $266,053.39 36
PY2024 Principal investigator $282,417.33 368
PY2023 Principal investigator $603,290.20 490
PY2022 Principal investigator $514,463.11 368
PY2021 Principal investigator $161,459.81 90
PY2020 Principal investigator $20,469.56 2
PY2019 Principal investigator $194,346.23 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 12/17/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692931
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 12/12/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220996494
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692927
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 11/07/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220996492
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,382.36 11/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clinical Atherosclerotic Cardiovascular Disease or at Risk for a First Atherosclerotic Cardiovascular Disease Event No dispute reported 06/30/2026 1185546195
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692925
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 10/27/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692929
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 10/08/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220996490
Principal investigator 1 Novartis Pharmaceuticals Corporation $123,245.53 10/06/2025 Non-covered Recipient Entity
JEFFERSON CITY MEDICAL GROUP, PC
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190303687
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692923
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 09/26/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220996488
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $391.52 09/22/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220802394
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,700.00 09/22/2025 Non-covered Recipient Entity
Qcare Site Services, Inc Avacare
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220812988
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692917
Principal investigator 1 Boehringer Ingelheim International GmbH $259.74 08/26/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692919
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 08/26/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692921
Principal investigator 1 Boehringer Ingelheim International GmbH $23.75 08/01/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692909
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 08/01/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692911
Principal investigator 1 Boehringer Ingelheim International GmbH $24.94 08/01/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692913
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Jefferson City Medical Group Admin Office
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. No dispute reported 06/30/2026 1220692915
Principal investigator 1 AstraZeneca Pharmaceuticals LP $44,127.07 07/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185546198
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,687.00 07/14/2025 Non-covered Recipient Entity
Jefferson City Medical Group
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215517366
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 07/14/2025 Non-covered Recipient Entity
Jefferson City Medical Group
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215517369
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,895.00 07/14/2025 Non-covered Recipient Entity
Jefferson City Medical Group
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215517373
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,200.00 07/14/2025 Non-covered Recipient Entity
Jefferson City Medical Group
Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2) No dispute reported 06/30/2026 1215517378
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 07/02/2025 Non-covered Recipient Entity
Jefferson City Medical Group
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215517351
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,520.00 07/02/2025 Non-covered Recipient Entity
Jefferson City Medical Group
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215517357
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,066.00 07/02/2025 Non-covered Recipient Entity
Jefferson City Medical Group
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215517362
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 07/02/2025 Non-covered Recipient Entity
Jefferson City Medical Group
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215517382
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,500.00 07/02/2025 Non-covered Recipient Entity
JEFFERSON CITY MEDICAL GROUP, PC
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185546201
Principal investigator 1 GlaxoSmithKline, LLC. $1,059.22 05/12/2025 Non-covered Recipient Entity
JEFFERSON CITY MEDICAL GROUP
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1192138652
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 02/28/2025 Non-covered Recipient Entity
Jefferson City Medical Group
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215517343
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 02/28/2025 Non-covered Recipient Entity
Jefferson City Medical Group
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215517347
Principal investigator 1 AstraZeneca UK Limited $16,039.00 02/21/2025 Non-covered Recipient Entity
JEFFERSON CITY MEDICAL GROUP, PC
A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment No dispute reported 06/30/2026 1185546193
Principal investigator 1 Alnylam Pharmaceuticals Inc. $30.00 01/31/2025 Non-covered Recipient Entity
Jefferson City Medical Group
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215517336
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 01/31/2025 Non-covered Recipient Entity
Jefferson City Medical Group
A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1) No dispute reported 06/30/2026 1215517339